The Mitral Valve Clinic (MVC) is a research clinic that has been collecting data from a population of dogs with MVD since 2004.

To date, over 450 dogs have been seen at the MVC. By recording information from lots of patients over a long period of time, the team of researchers working at the MVC have advanced the understanding of MVD in the dog and will continue to do so.

Dogs are enrolled in the clinic population on a voluntary basis and are examined every six months at no cost to the client. At each examination, dogs only undergo diagnostic tests that are routinely used by veterinary cardiologists to monitor MVD. These include: a physical examination, blood testing, urine testing, blood pressure monitoring, an electrocardiogram (ECG) and a cardiac ultrasound scan (echocardiography). All examinations are conducted without sedation or anaesthesia. As well as contributing to research, the results of these diagnostic tests are useful as they provide the client and their pet’s primary veterinary surgeon with information about their pet’s general health and disease status.

The data produced by the MVC have already been used to produce numerous publications on this topic and resulted in the award of three PhDs. Research conducted by members of the clinic has been used to advance our understanding of:

  • Echocardiographic monitoring of disease1,2
  • The use of blood borne biomarkers in MVD3,4
  • Cardiac fibrosis and MVD5,6
  • Vagal tone in MVD7
  • The prognostic value of information gained from a patient’s clinical history and physical examination8
  • Identifying patients at risk of having progressive disease (ongoing)

References

  1. Moonarmart W, Boswood A, Luis-Fuentes V, Elliott J. N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease. J Small Anim Pract. 2010;51: 84-96.
  2. Hezzell MJ, Boswood A, Moonarmart W, Elliott J. Selected echocardiographic variables change more rapidly in dogs that die from myxomatous mitral valve disease. J Vet Cardiol. 2012;14:269–79.
  3. Hezzell MJ, Boswood A, Lötter N, Elliott J. The effects of storage conditions on measurements of canine N-terminal pro-B-type natriuretic peptide. J Vet Cardiol. 2015;17:34-41.
  4. Hezzell MJ, Boswood A, Chang Y-M, Moonarmart W, Souttar K, Elliott J. The Combined Prognostic Potential of Serum High-Sensitivity Cardiac Troponin I and N-Terminal pro-B-Type Natriuretic Peptide Concentrations in Dogs with Degenerative Mitral Valve Disease. J Vet Intern Med. 2012;26:302-311
  5. Hezzell MJ, Boswood A, Chang YM, Moonarmart W, Elliott J. Associations among serum N-terminal procollagen type III concentration, urinaryaldosterone-to-creatinine ratio, and ventricular remodeling in dogs with myxomatous mitral valve disease. Am J Vet Res. 2012;73(11):1765–74.
  6. Hezzell MJ, Falk T, Olsen L, Boswood A, Elliott J. Associations between N-terminal procollagen type III, fibrosis and echocardiographic indices in dogs that died due to myxomatous mitral valve disease. J Vet Cardiol. 2014;16:257–64.
  7. López-Alvarez J, Boswood A, Moonarmart W, Hezzell MJ, Lotter N, Elliott J. Longitudinal Electrocardiographic Evaluation of Dogs with Degenerative Mitral Valve Disease. J Vet Intern Med. 2014 Mar;28(2):393–400.
  8. López-Alvarez JL, Elliott J, Pfeiffer D, Chang Y-M, Mattin M, Moonarmart W, et al. Clinical Severity Score System in Dogs with Degenerative Mitral Valve Disease. J Vet Intern Med. 2015 Mar; 29(2):575-581 .

Top of page